利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

121 条记录 (耗时 0.088 秒)

    GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF
    38.
    发明申请
    GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF 审中-公开
    与心血管疾病相关的遗传多态性与药物反应，检测方法及其用途

    公开(公告)号：US20150111775A1

    公开(公告)日：2015-04-23

    申请号：US14479916

    申请日：2014-09-08

    申请人： Celera Corporation

    发明人： Olga IAKOUBOVA ,  James J. DEVLIN

    IPC分类号： C12Q1/68

    摘要： The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual having a cardiovascular disorder to treatment of the disorder with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

    摘要翻译： 本发明基于与心血管疾病特别是急性冠状动脉事件（例如心肌梗死和中风）相关的遗传多态性的发现，以及与具有心血管疾病的个体的反应性相关的遗传多态性与该疾病的治疗相关 他汀 特别地，本发明涉及含有多态性的核酸分子，由该核酸分子编码的变体蛋白，用于检测多态核酸分子和蛋白质的试剂，以及使用该核酸和蛋白质的方法以及使用的方法 用于检测的试剂。

    LUNG CANCER MARKERS AND USES THEREOF
    39.
    发明申请
    LUNG CANCER MARKERS AND USES THEREOF 审中-公开
    肺癌标志物及其用途

    公开(公告)号：US20150037820A1

    公开(公告)日：2015-02-05

    申请号：US14331803

    申请日：2014-07-15

    申请人： Celera Corporation

    发明人： Charles BIRSE ,  Steve RUBEN ,  Marcia LEWIS ,  Mehdi MESRI

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57423 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57488 ,  G01N33/57492 ,  G01N2333/8114 ,  G01N2333/96486 ,  G01N2800/56

    摘要： Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.

    摘要翻译： 提供了使用肺癌标志物（LCM）评估（例如诊断），治疗和预防疾病，特别是癌症和特定肺癌的方法和组合物。 为这些和其他用途提供了单个LCM和包含多个LCM的面板。 还提供了用于确定或预测治疗的有效性或使用LCM选择治疗的方法和组合物。 还提供了使用LCM调节细胞功能的方法和组合物。 还提供了调节LCM的组合物（例如拮抗剂或激动剂），例如抗体，蛋白质，小分子化合物和核酸试剂（例如RNAi和反义剂），以及其药物组合物。 还提供了筛选调节LCM的试剂的方法以及通过这些筛选方法鉴定的试剂。